{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:34:44Z","timestamp":1789817684168,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":1505,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Union Internationale de Phl\u00e9bologie 2018 Research Fellowship Kreussler Young Scientists\u2019 Sclerotherapy"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvsvenous.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jvsv.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T13:28:47Z","timestamp":1596115727000},"page":"154-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Reducing hyperpigmentation after sclerotherapy: A randomized clinical trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Alejandro Jose","family":"Gonzalez Ochoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Manr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Nuricumbo","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvsv.2020.06.019_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0268355513483280","article-title":"European guidelines for sclerotherapy in chronic venous disorders","volume":"29","author":"Rabe","year":"2014","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jvsv.2017.02.002","article-title":"Cosmetic sclerotherapy","volume":"5","author":"Watson","year":"2017","journal-title":"J\u00a0Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jvsv.2020.06.019_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.113.006898","article-title":"Chronic venous insufficiency","volume":"130","author":"Eberhardt","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jvsv.2020.06.019_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0268355514534648","article-title":"Interaction of detergent sclerosants with cell membranes","volume":"30","author":"Parsi","year":"2014","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejvs.2010.10.004","article-title":"In\u00a0vitro effects of detergent sclerosants on clot formation and fibrinolysis","volume":"41","author":"Parsi","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejvs.2015.11.011","article-title":"Media damage following detergent sclerotherapy appears secondary to the induction of inflammation and apoptosis: an immunohistochemical study elucidating previous histological observations","volume":"51","author":"Whiteley","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib7","series-title":"Low concentration sclerotherapy (Casoni's method): systemic effects on cytokines and immunoglobulins","author":"Manello","year":"2019"},{"key":"10.1016\/j.jvsv.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/026835550201700105","article-title":"Treatment of varicose veins by foam sclerotherapy: two clinical series","volume":"17","author":"Cavezzi","year":"2002","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0268355516642659","article-title":"Sclerotherapy is a safe method of treatment of chronic venous disorders in older patients: a prospective and comparative study of consecutive patients","volume":"32","author":"Gillet","year":"2018","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib10","series-title":"Evidence-based procedural dermatology","first-page":"389","article-title":"Small caliber vessel sclerotherapy","author":"Cartee","year":"2012"},{"key":"10.1016\/j.jvsv.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jamadermatol.2017.3426","article-title":"Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial","volume":"157","author":"Bertanha","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jvsv.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1258\/phleb.2012.012s09","article-title":"Complications of foam sclerotherapy","volume":"27","author":"Cavezzi","year":"2012","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0741-5214(03)00920-0","article-title":"Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial","volume":"38","author":"Scultetus","year":"2003","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.23736\/S0392-9590.16.03718-4","article-title":"Sulodexide and phlebotonics in the treatment of venous ulcers","volume":"36","author":"Gonzalez-Ochoa","year":"2017","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib15","first-page":"1","article-title":"Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence","volume":"27","author":"Nicolaides","year":"2008","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.23736\/S0392-9590.17.03805-6","article-title":"Chronic venous disease treated with sulodexide","volume":"36","author":"Flota Cervera","year":"2017","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.14324","article-title":"Sulodexide in venous disease","volume":"17","author":"Carroll","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","article-title":"Sulodexide for the prevention of recurrent venous thromboembolism: the SURVET study: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"132","author":"Andreozzi","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jvsv.2020.06.019_bib19","series-title":"Vascular and endovascular controversies update: 40 years looking forward","first-page":"491","article-title":"Reducing hyperpigmentation after sclerotherapy using antithrombotic drug","author":"Gonzalez-Ochoa","year":"2018"},{"key":"10.1016\/j.jvsv.2020.06.019_bib20","series-title":"Aethoxysclerol [brochure]","year":"2019"},{"key":"10.1016\/j.jvsv.2020.06.019_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/DSS.0000000000000225","article-title":"Consensus for sclerotherapy","volume":"40","author":"Weiss","year":"2014","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jvs.2007.02.039","article-title":"Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study","volume":"45","author":"Kern","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib23","first-page":"53","article-title":"Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins","volume":"35","author":"Nootheti","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejvs.2019.08.020","article-title":"Post-procedural compression vs. no compression after radiofrequency ablation and concomitant foam sclerotherapy of varicose veins: a randomised controlled non-inferiority trial","volume":"59","author":"Pihlaja","year":"2020","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jvsv.2019.07.008","article-title":"Elastic compression after ultrasound-guided foam sclerotherapy in overweight patients does not improve primary venous hemodynamics outcomes","volume":"8","author":"Campos Gomes","year":"2020","journal-title":"J\u00a0Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jvsv.2020.06.019_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/rth2.12049","article-title":"Randomized, double-blind, placebo-controlled, interventional phase IV investigation to assess the efficacy and safety of r-hirudin gel (1120I.U) in patients with hematomas","volume":"2","author":"El-Mowafi","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jvsv.2020.06.019_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2165\/00044011-200828100-00001","article-title":"Topically applied heparins for the treatment of vascular disorders: a comprehensive review","volume":"28","author":"Vecchio","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jvsv.2020.06.019_bib28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1524-4725.1990.tb01563.x","article-title":"Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol","volume":"16","author":"Weiss","year":"1990","journal-title":"J\u00a0Dermatol Surg Oncol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib29","first-page":"CD008826","article-title":"Sclerotherapy for lower limb telangiectasias","volume":"12","author":"Schwartz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2020.06.019_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1258\/phleb.2011.011111","article-title":"Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders","volume":"27","author":"Rathbun","year":"2012","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib31","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.21149\/spm.v55s2.5111","article-title":"Prevalence of obesity in Mexican adults 2000-2012","volume":"55","author":"Barquera","year":"2013","journal-title":"Salud Publica Mex"},{"key":"10.1016\/j.jvsv.2020.06.019_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DMSO.S129247","article-title":"Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences","volume":"11","author":"DiBonaventura","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jvsv.2020.06.019_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1258\/phleb.2009.009043","article-title":"Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study)","volume":"25","author":"Rabe","year":"2010","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2020.06.019_bib34","first-page":"18","article-title":"Survey on skin tone detection using color spaces","volume":"2","author":"Prema","year":"2012","journal-title":"Int J Appl Inf Syst"},{"key":"10.1016\/j.jvsv.2020.06.019_bib35","first-page":"1031","article-title":"Vein imaging: a new method of near infrared imaging, where a processed image is projected on to the skin for the enhancement of vein treatment","volume":"32","author":"Miyake","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jvsv.2020.06.019_bib36","series-title":"Vascular and endovascular challenges update","article-title":"Laser treatment of reticular and subcuticular veins (CLaCS) guided by augmented reality","author":"Miyake","year":"2016"},{"key":"10.1016\/j.jvsv.2020.06.019_bib37","series-title":"Enfermedades venosas: diagnostico y tratamiento","first-page":"343","author":"Guerrero","year":"2013"},{"key":"10.1016\/j.jvsv.2020.06.019_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23736\/S0392-9590.17.03868-8","article-title":"Benefits of micronized purified flavonoid fraction as adjuvant therapy on the inflammatory response after sclerotherapy","volume":"37","author":"Bogachev","year":"2018","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib39","first-page":"229","article-title":"Pharmacological profile of sulodexide","volume":"33","author":"Hoppensteadt","year":"2014","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1570161111311030010","article-title":"Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in chronic vascular disease","volume":"11","author":"Mannello","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19061669","article-title":"Pathophysiological mechanisms of chronic venous disease and implication for venoactive drug therapy","volume":"19","author":"Mansilha","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jvsv.2020.06.019_bib42","first-page":"589","article-title":"Sulodexide suppresses inflammation in patients with chronic venous insufficiency","volume":"34","author":"Urbanek","year":"2015","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2020.06.019_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fped.2018.00142","article-title":"The role of inflammation in thromboembolism","volume":"6","author":"Branchford","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jvsv.2020.06.019_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.pmbts.2019.02.005","article-title":"Heparinoids danaparoid and sulodexide as clinically used drugs","volume":"163","author":"Dou","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.jvsv.2020.06.019_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1534734614534442","article-title":"Sulodexide as adjunctive therapy in diabetic foot patients with critical limb ischemia treated with percutaneous transluminal angioplasty","volume":"13","author":"Piaggesi","year":"2014","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.jvsv.2020.06.019_bib46","first-page":"182","article-title":"Benefit of Daflon 500 mg in combination with sclerotherapy of telangiectasias of the lower limbs: results from the SYNERGY and SATISFY surveys","volume":"19","author":"Pitsch","year":"2011","journal-title":"Phlebolymphology"}],"container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X20304182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X20304182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:02:15Z","timestamp":1761980535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213333X20304182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2213333X20304182"],"URL":"https:\/\/doi.org\/10.1016\/j.jvsv.2020.06.019","relation":{},"ISSN":["2213-333X"],"issn-type":[{"value":"2213-333X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing hyperpigmentation after sclerotherapy: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery: Venous and Lymphatic Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvsv.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}